USPTO serial 79134622
KANGAROO ISLAND NATURALS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 10, 2015
- Examiner
- MCCAULEY, BRENDAN D
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KANGAROO ISLAND NATURALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Kangaroo Island Natural Products Pty Ltd
GUILDFORD NSW, AU
Other trademarks owned by Kangaroo Island Natural Products Pty Ltd
Kangaroo Island Natural Products Pty Ltd
GUILDFORD NSW 2161, AU
Other trademarks owned by Kangaroo Island Natural Products Pty Ltd
Kangaroo Island Natural Products Pty Ltd
GUILDFORD NSW 2161, AU
Other trademarks owned by Kangaroo Island Natural Products Pty Ltd
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Howard A. MacCord, Jr.
Howard A. MacCord, Jr. MACCORD MASON PLLC2733 Horse Pen Creek Road, Suite 101GREENSBORO, NC 27410UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | [ Cosmetics being anti-sun preparations, namely, cosmetic preparations for protecting the skin from the sun's rays, cosmetic sun-protecting preparations and non-medicated sun care preparations; ] Cosmetics, namely, body creams; [ cleaning oils for cosmetic purposes; cosmetic acne cleansers, namely, facial cleaning preparation in the nature of salicylic acne cleanser not for medical purposes and non-medicated acne treatment preparations; cosmetic bath products, namely, bath lotions, bath gels and bubble bath; cosmetic cotton wool; cosmetic preparations for cleansing the mouth, namely, mouth washes and non-medicated mouth rinse; cosmetics; cosmetics for animals; cosmetics for protecting the skin from sunburn; ] cosmetics for the treatment of dry skin; cosmetics for the use on the hair; cosmetics for use on the skin; cosmetics preparations; [ cotton pads for cosmetic use; facial wipes impregnated with cosmetics; hair cosmetics; ] cosmetics, namely, moisturizers; [ cosmetics, namely, nail preparation; ] cosmetic nourishing creams; [ cosmetic oils for the skin; non-medicated cosmetic skin balms; ] cosmetics, namely, non-medicated skin care creams; cosmetics, namely, non-mediates skin care lotions; [ cosmetic skin care oils, namely, body oil and face oil; ] cosmetics, namely, non-medicated skin care preparations; cosmetic skin care products, namely, cosmetic creams for skin care, cosmetic preparations for skin care and non-medicated skin serum; non-medicated cosmetic skin cleansing preparations [ ; cosmetics being sun barriers, namely, sun block; cosmetics, namely, sun blocking preparations; cosmetics being sun protection products, namely, sun screen and sun screen preparations; cosmetic sun skin care products, namely, after sun creams, gels and lotions ] | SECTION 70 - CANCELLED | — |
| 005 | [ Pharmaceutical preparations in the nature of acne cleansers for the treatment of acne, anti-bacterials, antifungals, antiviruses and anti-septics for the treatment of skin and soft tissue infections, scalp infections and disorder conditions, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, cardiovascular system infections, systemic infections, urinal tract infections and bacterial vaginosis; Pharmaceutical preparations for the treatment of skin and soft tissue infections, namely, leprosy, carbuncles, staph infections, erysipelas, cellulitis, necrotizing fasciitis, boils, pilonidal cysts and abscesses, impetigo, eczema, psoriasis, seborrheic dermatitis, acne and pimples, wound infections, minor burns, skin ulcers and abrasions, infection of fingernails, toenails and nail beds, ingrown nails, athlete's foot, jock itch, ringworm, yeast infections, cutaneous candidiasis, tinea versicolour, sporotrichosis, molluscum contagiosum, shingles, chickenpox and herpes stomatitis; Pharmaceutical preparations for the treatment of skin disorders, namely, wrinkles, freckles, melasma, varicose veins, flaking skin, eczema, acne, psoriasis, stretch marks, severe dry skin, cracked skin, itching, scaling and scars, skin aging, burns, wound ulcers, seborrhoeic keratoses, warts, pemphigoid, actinic keratosis, lupus, dermatomyositis, vitiligo, keloid, ichthyosis vulgaris, molluscum contagiosum, shingles, chickenpox, herpes stomatitis and vaginal atrophy; Pharmaceutical preparations for the treatment of scalp infections and disorder conditions, namely, dandruff, inflammatory hair loss and folliculitis; Pharmaceutical preparations for the treatment of oral and dental infections, namely, mouth gum and throat infections, mouth ulcers, mouth deodorant and cold sores; Pharmaceutical preparations for the treatment of allergies, namely, hives, lichen planus, insect bites and stings, skin allergies, skin rashes, nappy rash, heat rash and sweat rash; Pharmaceutical preparations for the treatment of sun damage, namely, sun burn, rosacea, solar keratoses, sun spots, skin lesions and melanoma; Pharmaceutical preparations for the treatment of pain and inflammation, muscle, joint and bone disorders, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders, diabetic and metabolic disorders; Pharmaceutical preparations for health care, namely, antimicrobials, namely, Amoxicillin, Cephalexin, Mupirocin, and Chloramphenicol; antifungal pharmaceutical products, namely, Clotrimazole, Fluconazole, and Terbinafine; anti-yeast pharmaceutical products, namely, Nystatin, and Clotrimazole; antivirus pharmaceutical products, namely, Aciclovir, Famciclovir, and Oseltamivir; anti-septic pharmaceutical products, namely, Cetrimide, Chlorhexidine, and tea tree oil for medical purposes; anti-aging pharmaceutical products, namely, Vitamin A, Vitamin C, Alpha Hydroxy acids, Retinol, Collagen, Elastin, and Resveratrol; anti-oxidant pharmaceutical products, namely, Vitamin E, Lycopene, Resveratrol, and Coenzyme Q10; analgesic and anti-inflammation pharmaceutical products, namely, Aspirin, Ibuprofen, Paracetamol, Celecoxib, Meloxicam, and Corticosteroid; anti-sun care pharmaceutical products, namely, Tretinoin, Avobenzone, Butyl methoxydibenzoylmethane, Homosalate, Octinoxate, Octisalate, Octocrylene, Oxybenzone, Titanium dioxide, and Zinc Oxide; after sun care pharmaceutical products, namely, aloe vera for therapeutic purposes, Vitamin B5, Vitamin C, Vitamin E, and petroleum jelly for medical purposes; skin lesion care pharmaceutical products, namely, Fluorouracil, and Imiquimod; skin and body care pharmaceutical products, namely, Tretinoin, Calcipotriol, Coal tar for medical purposes, Benzoyl peroxide, Resorcinol, Salicylic acid, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone, Cetrimide, Chlorhexidine, Vitamin B5, Vitamin C, Vitamin E, Urea, and petroleum jelly for medical purposes; face care pharmaceutical products, namely, Isotretinoin, Benzoyl peroxide, Resorcinol, and Salicylic acid; nail care pharmaceutical products, namely, Amorolfine, Ciclopirox, Clotrimazole, and Terbinafine; burn and wound care pharmaceutical products, namely, Tea tree oil for medical purposes, Medihoney, and Silver sulfadiazine; peripheral circulatory care pharmaceutical products, namely, Chilblain cream, and Gingko biloba tablets for medical purposes; muscle, joint and bone care pharmaceutical products, namely, fish oil for medical purposes, krill oil for medical purposes, Glucosamine and Chondroitin, and Vitamin D; health tonic pharmaceutical products, namely, panax ginseng tablets for medical purposes and ginger tablets for medical purposes; hair and scalp care pharmaceutical products, namely, coal tar for medical purposes, Pinetar for medical purposes, Ciclopirox, Ketoconazole, Mometasone furoate, Piroctone olamine, Salicylic acid, Selenium, Vitamin E, and Zinc pyrithione; cardiovascular protection pharmaceutical products, namely, Aspirin, Atorvastatin, Simvastatin, Rosuvastatin, Resveratrol, and Coenzyme Q10; anti-lipidemia pharmaceutical products, namely, Atorvastatin, Simvastatin, Rosuvastatin, and Fenofibrate; diabetic type 2 care pharmaceutical products, namely, Metformin, Gliclazide, and Resveratrol; anti-allergy pharmaceutical products, namely, Fexofenadine, Cetirizine, Levocetirizine, Betamethasone, Hydrocortisone, Mometasone furoate, Methylprednisolone, and Triamcinolone; insect bites and sting pharmaceutical products, namely, Aluminium sulfate, Cetrimide, Chlorhexidine, and tea tree oil for medical purposes; modulation of immunity pharmaceutical products, namely, Corticosteroid, Cyclosporine, Azathioprine, and Leflunomide; respiratory care pharmaceutical products, namely, Bromhexine, Ipratropium, Salbutamol, Corticosteroid, Tiotropium, and Montelukast; gastro-intestinal tract care pharmaceutical products, namely, Hyoscine butylbromide, Esomeprazole, Omeprazole, and Pantoprazole; Pharmaceutical preparations in the form of lotions, namely, pharmaceutical skin lotions, pharmaceutical preparations in the form of lozenges, namely, medicated lozenges and throat lozenges, pharmaceutical preparations in the form of tablets, namely, allergy tablets and antibiotic tablets; Pharmaceutical moisturizing preparations, namely, medicated skin moisturizers, for use on the skin for the treatment of wrinkles, freckles, melasma, varicose vein, flaking skin, eczema, acne, psoriasis, stretch marks, severe dry skin, cracked skin, itching, scaling and scars, skin aging, burns, wound ulcers, seborrhoeic keratoses, warts, pemphigoid, actinic keratosis, lupus, dermatomyositis, vitiligo, keloid, ichthyosis vulgaris, molluscum contagiosum, shingles, chickenpox, herpes stomatitis, insect bites and stings, skin allergies, hives, lichen planus, skin rashes, nappy rash, heat rash, sweat rash, vaginal atrophy, rosacea, sun damage, sun burn, solar keratoses, sun spots, skin lesion and melanoma; Pharmaceutical preparations for use in the treatment of skin blemishes, in the nature of acne cleansers, namely, liver spots, purpura, seborrheic keratoses, acne, pimples, skin disclouration, dark spots, red spots, white heads, black heads, papules, pustule, rosacea, cystic acne, nodules, sun damaged skin and aging skin; Pharmaceutical preparations for application to the scalp for the treatment of inflammatory hair loss, Tinea capitis, trichotillomania, alopecia areata, seborrheic eczema, dermatitis, cradle cap, psoriasis, dandruff or pityriasis capitis, pityriasis amiantacea, lichen simplex, folliculitis, scalp infection, hair loss, baldness, hair thinning conditions and hair shaft abnormalities; Pharmaceutical preparations for application to the nails for the treatment of eczema, dermatitis and psoriasis of the nail fold, paronychia, fungal infection, onychomycosis, tinea, and athlete's foot, inflammation of the nail fold, nail discoloration and nail thickening; Pharmaceutical preparations for skin care and topical use, namely, Mupirocin, Polymyxin B, Neomycin, Bacitracin, Terbinafine, Clotrimazole, Nystatin, Aciclovir, Penciclovir, Amorolfine, Ciclopirox, Itraconazole, Fluconazole, Ketoconazole, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone, Mometasone furoate, Isotretinoin, Calcipotriol, Coal tar for medical purposes, Pinetar for medical purposes, Piroctone olamine, Benzoyl peroxide, Resorcinol, Salicylic acid, Selenium, Zinc pyrithione, Silver sulfadiazine, Chilblain cream, Aluminium sulfate, Tea tree oil for medical purposes, Cetrimide, Chlorhexidine, Vitamin B5, Vitamin C, Vitamin E, Urea, Petroleum for medical purposes, Tretinoin, Avobenzone, Butyl methoxydibenzoylmethane, Homosalate, Octinoxate, Octisalate, Octocrylene, Oxybenzone, Titanium dioxide, Zinc Oxide, Fluorouracil and Imiquimod; Pharmaceutical preparations for animals for the treatment of skin and soft tissue infections, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, urinary tract infections, cardiovascular system infections, systemic infections, severe sepsis, wound ulcers, burns, skin lesions, melanoma, pain and inflammation, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders, muscle, joint and bone disorders, and diabetic and metabolic disorders; Pharmaceutical preparations for veterinary use, namely, parasiticides and dermatological preparations, namely, Azoles, Fipronil, Imidacloprid, Ivermectin, and Pyrantel; antibiotics pharmaceutical products, namely, Amoxicillin, and Cephalexin; immunotherapy pharmaceutical products, namely, Cyclosporin, and Corticosteroids; nutrition and metabolism pharmaceutical products, namely, Omega-3, and fish oil for medical purposes; musculosketal system pharmaceutical products, namely, Firocoxib, Meloxicam, and fish oil for medical purposes; pain and inflammation pharmaceutical products, namely, Aspirin, Ibuprofen, Firocoxib, Meloxicam, and Naproxen; allergy pharmaceutical products, namely, Clemastine, Chlorpheniramine, Hydroxyzine, Fexofenadine, Cetirizine, and Prednisone; cardiovascular protection pharmaceutical products, namely, Aspirin, and Moxidectin; respiratory pharmaceutical products, namely, Bromhexine, Albuterol, and Corticosteroids; gastro-intestinal tract pharmaceutical products, namely, Hyoscine butylbromide; ] Propolis for pharmaceutical purposes, namely, propolis for medicinal or therapeutic purposes, namely, propolis cream [, propolis lotion, propolis liquid, propolis lozenges and propolis softgel capsules, to treat skin and soft tissue infections and disorder conditions, nail infections and disorder conditions, scalp infections and disorder conditions, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, cardiovascular system infections, systemic infections, urinal tract infections, bacterial vaginosis, itching, allergies, insect bites and stings, rashes, sun burns, rosacea, solar keratoses, skin lesions, melanoma, pain and inflammation, muscle, joint and bone disorders, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders and diabetic and metabolic disorders; Plant extracts for pharmaceutical use, namely, plant extracts for pharmaceutical purposes, namely, Gingko biloba for medical purposes, Ginger and Panax ginseng for medical purposes, to treat skin and soft tissue infections and disorder conditions, nail infections and disorder conditions, scalp infection and disorder conditions, oral and dental infections, eye and ear infections, respiratory tract infections, gastro-intestinal tract infections, cardiovascular system infections, systemic infections, urinal tract infections, bacterial vaginosis, itching, allergies, insect bites and stings, rashes, sun burn, rosacea, solar keratoses, skin lesions, melanoma, pain and inflammation, muscle, joint and bone disorders, cardiovascular diseases, hyperlipidemia, peripheral circulatory disorders and diabetic and metabolic disorders; Pharmaceutical products derived from natural sources, namely, Amrubicin, Daptomycin, Galantamine, Mycophenolic acid, Nitisinone, Omegacin, Pitavastatin, Rosuvastatin, Fish oil for medical purposes, Krill oil for medical purposes, Vitamin E, Vitamin D, Vitamin C, Collagen Elastin, Lycopene, Selenium, Glucosamine and Chondroitin, Panax ginseng for medical purposes, Ginger for medical purposes, Gingko biloba for medical purposes and Resveratrol; Pharmaceutical preparations containing royal jelly for the treatment of hypertension, hyperlipidemia, inflammation, asthma, hay fever, sleep disorders, insomnia, premenstrual syndrome, stomach ulcers, menopause symptoms, skin disorders, skin nutrition, health tonic, anti-aging, boosting immune system, and hair nutrition; Oils for pharmaceutical purposes, namely, Tea tree oil, Eucalyptus oil, Clove oil, Cinnamon oil, Benzoin oil and Citronella oil all for medical purposes ] | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kangaroo Island Natural Products Pty Ltd
- Other trademarks owned by Kangaroo Island Natural Products Pty Ltd
- Other trademarks owned by Kangaroo Island Natural Products Pty Ltd
- Other trademarks in Class 003
- Other trademarks in Class 005
- Similar marks named KANGAROO ISLAND NATURALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 2, 2023 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Dec 2, 2023 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Feb 6, 2023 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Dec 7, 2022 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Dec 7, 2022 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Nov 10, 2022 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Mar 10, 2022 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Mar 10, 2022 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Mar 4, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 9, 2021 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Sep 17, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 17, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 17, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 17, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 17, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 10, 2020 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 7, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 22, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 22, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 10, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 10, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 13, 2015 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 28, 2015 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 28, 2015 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 23, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 23, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 19, 2014 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 3, 2014 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 3, 2014 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 3, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 18, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 10, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 10, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 10, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 10, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 10, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 7, 2014 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 2, 2014 | PBTQ | WITHDRAWN FROM PUB OTQR REQUEST | — |
| Sep 22, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 19, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 12, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 12, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 12, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 28, 2014 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Aug 28, 2014 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 28, 2014 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 14, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 14, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 8, 2014 | ALIE | ASSIGNED TO LIE | — |
| Aug 6, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 25, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 25, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 25, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 18, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 18, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 18, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 30, 2013 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 6, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 6, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 6, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 5, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 27, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 23, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 22, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |